Etiopathogenesis of inflammatory bowel disease: Today and tomorrow

Current Opinion in Gastroenterology

Volumn 33, Issue 4, 2017, Pages 222-229

  De Souza, Heitor S P ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

Author keywords

diet; epigenetics; inflammatory bowel disease; interactome; microbiome

Indexed keywords

INFLAMMASOME;

DIET; ENVIRONMENTAL FACTOR; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTRACELLULAR SIGNALING; MEDICAL LITERATURE; PATHOGENESIS; REVIEW; EPIGENETICS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLOMICS; PATHOPHYSIOLOGY; PROTEOMICS; RISK FACTOR; SYSTEMS BIOLOGY; WESTERN DIET;

DIET, WESTERN; EPIGENOMICS; GASTROINTESTINAL MICROBIOME; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; METABOLOMICS; PROTEOMICS; RISK FACTORS; SYSTEMS BIOLOGY;

EID: 85017567367     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000364     Document Type: Review

References (77)

1. Rogler G, Zeitz J, Biedermann L. The search for causative environmental factors in inflammatory bowel disease. Dig Dis 2016; 34 (Suppl 1):48-55.
2. Rehman A, Rausch P, Wang J, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut 2016; 65:238-248.
3. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: A population-based case-control study in Asia-Pacific. Gut 2015; 64:1063-1071.
4. Benchimol EI, Mack DR, Guttmann A, et al. Inflammatory bowel disease in immigrants to Canada and their children: A population-based cohort study. Am J Gastroenterol 2015; 110:553-563.
5. Kraiczy J, Nayak K, Ross A, et al. Assessing DNA methylation in the developing human intestinal epithelium: potential link to inflammatory bowel disease. Mucosal Immunol 2016; 9:647-658.
6. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15:382-392.
7. Li KY, Wang JL, Wei JP, et al. Fecal microbiota in pouchitis and ulcerative colitis. World J Gastroenterol 2016; 22:8929-8939.
8. Takeshita K, Mizuno S, Mikami Y, et al. A single species of Clostridium subcluster XIVa decreased in ulcerative colitis patients. Inflamm Bowel Dis 2016; 22:2802-2810.
9. Natividad JM, Pinto-Sanchez MI, Galipeau HJ, et al. Ecobiotherapy rich in Firmicutes decreases susceptibility to colitis in a humanized gnotobiotic mouse model. Inflamm Bowel Dis 2015; 21:1883-1893.
10. Heinsen FA, Knecht H, Neulinger SC, et al. Dynamic changes of the luminal andmucosa-associated gut microbiota during and after antibiotic therapy with paromomycin. Gut Microbes 2015; 6:243-254.
11. Takahashi K, Nishida A, Fujimoto T, et al. Reduced abundance of butyrateproducing bacteria species in the fecal microbial community in Crohn's disease. Digestion 2016; 93:59-65.
12. Hedin C, van der Gast CJ, Rogers GB, et al. Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities. Gut 2016; 65:944-953.
13. Wright EK, Kamm MA, Teo SM, et al. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: A systematic review. Inflamm Bowel Dis 2015; 21:1219-1228.
14. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 2011; 106:2133-2142.
15. Basic M, Keubler LM, Buettner M, et al. Norovirus triggered microbiota-driven mucosal inflammation in interleukin 10-deficient mice. Inflamm Bowel Dis 2014; 20:431-443.
16. Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015; 160:447-460.
17. Mokry M, Middendorp S, Wiegerinck CL, et al. Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology 2014; 146:1040-1047.
18. Kaser A, Pasaniuc B. IBD genetics: focus on (dys) regulation in immune cells and the epithelium. Gastroenterology 2014; 146:896-899.
19. Hoefkens E, Nys K, John JM, et al. Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. Autophagy 2013; 9:2046-2055.
20. Salem M, Ammitzboell M, Nys K, et al. ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy 2015; 11:585-594.
21. Hosomi S, Kaser A, Blumberg RS. Role of endoplasmic reticulum stress and autophagy as interlinking pathways in the pathogenesis of inflammatory bowel disease. Curr Opin Gastroenterol 2015; 31:81-88.
22. Adolph TE, Tomczak MF, Niederreiter L, et al. Paneth cells as a site of origin for intestinal inflammation. Nature 2013; 503:272-276.
23. Tschurtschenthaler M, Adolph TE, Ashcroft JW, et al. Defective ATG16L1-mediated removal of IRE1alpha drives Crohn's disease-like ileitis. J Exp Med 2017; 214:401-422.
24. Birchenough GM, Johansson ME, Gustafsson JK, et al. New developments in goblet cell mucus secretion and function. Mucosal Immunol 2015; 8:712-719.
25. Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep 2015; 16:164-177.
26. Johansson ME, Gustafsson JK, Holmen-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014; 63:281-291.
27. Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013; 14:221-229.
28. Buela KA, Omenetti S, Pizarro TT. Cross-talk between type 3 innate lymphoid cells and the gut microbiota in inflammatory bowel disease. Curr Opin Gastroenterol 2015; 31:449-455.
29. Lopez-Posadas R, Becker C, Gunther C, et al. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. J Clin Invest 2016; 126:611-626.
30. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015; 372:1104-1113.
31. Monteleone G, Di Sabatino A, Ardizzone S, et al. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment Pharmacol Ther 2016; 43:717-724.
32. Monteleone I, Marafini I, Zorzi F, et al. Smad7 knockdown restores aryl hydrocarbon receptor-mediated protective signals in the gut. J Crohns Colitis 2016; 10:670-677.
33. Lavin Y, Winter D, Blecher-Gonen R, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014; 159:1312-1326.
34. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 2014; 157:832-844.
35. Zigmond E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 2014; 40:720-733.
36. Gabanyi I, Muller PA, Feighery L, et al. Neuro-immune interactions drive tissue programming in intestinal macrophages. Cell 2016; 164:378-391.
37. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013; 76:1-8.
38. Sandborn WJ, Panes J, Zhang H, et al. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology 2016; 150:96-102.
39. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12:1485-1493. e2.
40. Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut Published Online First: 16 February 2017. doi: 10. 1136/gutjnl-2016-312735
41. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016; 375:1946-1960.
42. Opipari A, Franchi L. Role of inflammasomes in intestinal inflammation and Crohn's disease. Inflamm Bowel Dis 2015; 21:173-181.
43. Vanhove W, Peeters PM, Staelens D, et al. Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease. Inflamm Bowel Dis 2015; 21:2673-2682.
44. Ratsimandresy RA, Indramohan M, Dorfleutner A, Stehlik C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol 2017; 14:127-142.
45. Liu L, Dong Y, Ye M, et al. The pathogenic role of NLRP3 inflammasome activation in inflammatory bowel diseases of both mice and humans. J Crohns Colitis 2017; jjw219. doi: 10. 1093/ecco-jcc/jjw219. [Epub ahead of print]
46. Chen X, Li L, Khan MN, et al. HMGB1 exacerbates experimental mouse colitis by enhancing innate lymphoid cells 3 inflammatory responses via promoted IL-23 production. Innate Immun 2016; 22:696-705.
47. Carpenter S. Editorial: functions of non-coding RNA in innate immunity. Front Immunol 2015; 6:622.
48. Stachurska A, Zorro MM, van der Sijde MR, Withoff S. Small and long regulatory RNAs in the immune system and immune diseases. Front Immunol 2014; 5:513.
49. Gazouli M, Papaconstantinou I, Stamatis K, et al. Association study of genetic variants in miRNAs in patients with inflammatory bowel disease: preliminary results. Dig Dis Sci 2013; 58:2324-2328.
50. Cheng X, Zhang X, Su J, et al. miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease. Sci Rep 2015; 5:10397.
51. Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/ Th17 cell immune responses in IBD. Gut 2015; 64:1755-1764.
52. Koukos G, Polytarchou C, Kaplan JL, et al. A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inflamm Bowel Dis 2015; 21:996-1005.
53. Sarmento OF, Svingen PA, Xiong Y, et al. The role of the histone methyltransferase enhancer of zeste homolog 2 (EZH2) in the pathobiological mechanisms underlying inflammatory bowel disease (IBD). J Biol Chem 2017; 292:706-722.
54. Fogel O, Richard-Miceli C, Tost J. Epigenetic changes in chronic inflammatory diseases. Adv Protein Chem Struct Biol 2017; 106:139-189.
55. Duffy LC, Raiten DJ, Hubbard VS, Starke-Reed P. Progress and challenges in developing metabolic footprints from diet in human gut microbial cometabolism. J Nutr 2015; 145:1123S-1130S.
56. Davis EC, Wang M, Donovan SM. The role of early life nutrition in the establishment of gastrointestinal microbial composition and function. Gut Microbes 2017; 8:143-171.
57. Voreades N, Kozil A, Weir TL. Diet and the development of the human intestinal microbiome. Front Microbiol 2014; 5:494.
58. Lee HS. Impact of maternal diet on the epigenome during in utero life and the developmental programming of diseases in childhood and adulthood. Nutrients 2015; 7:9492-9507.
59. Navarro E, Funtikova AN, Fito M, Schroder H. Prenatal nutrition and the risk of adult obesity: long-term effects of nutrition on epigenetic mechanisms regulating gene expression. J Nutr Biochem 2017; 39:1-14.
60. Fernandez-Twinn DS, Constancia M, Ozanne SE. Intergenerational epigenetic inheritance in models of developmental programming of adult disease. Semin Cell Dev Biol 2015; 43:85-95.
61. Castro Aguilar-Tablada T, Navarro-Alarcon M, Quesada Granados J, et al. Ulcerative colitis and Crohn's disease are associated with decreased serum selenium concentrations and increased cardiovascular risk. Nutrients 2016; 8:E780.
62. Monteiro CA, Moubarac JC, Cannon G, et al. Ultra-processed products are becoming dominant in the global food system. Obes Rev 2013; 14 (Suppl 2): 21-28.
63. Kaushal N, Kudva AK, Patterson AD, et al. Crucial role of macrophage selenoproteins in experimental colitis. J Immunol 2014; 193:3683-3692.
64. Kudva AK, Shay AE, Prabhu KS. Selenium and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015; 309:G71-G77.
65. Reed S, Neuman H, Moscovich S, et al. Chronic zinc deficiency alters chick gut microbiota composition and function. Nutrients 2015; 7:9768-9784.
66. Liu X, Wu Y, Li F, Zhang D. Dietary fiber intake reduces risk of inflammatory bowel disease: result from a meta-analysis. Nutr Res 2015; 35:753-758.
67. Hu Y, Le Leu RK, Christophersen CT, et al. Manipulation of the gut microbiota using resistant starch is associated with protection against colitis-associated colorectal cancer in rats. Carcinogenesis 2016; 37:366-375.
68. Wang H, Shi P, Zuo L, et al. Dietary nondigestible polysaccharides ameliorate intestinal epithelial barrier dysfunction in IL-10 knockout mice. J Crohns Colitis 2016; 10:1076-1086.
69. Hung TV, Suzuki T. Dietary fermentable fiber reduces intestinal barrier defects and inflammation in colitic mice. J Nutr 2016; 146:1970-1979.
70. Lewis JD, Abreu MT. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology 2017; 152:398-414 e6.
71. Charlebois A, Rosenfeld G, Bressler B. The impact of dietary interventions on the symptoms of inflammatory bowel disease: A systematic review. Crit Rev Food Sci Nutr 2016; 56:1370-1378.
72. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis 2014; 20:1353-1360.
73. Olendzki BC, Silverstein TD, Persuitte GM, et al. An anti-inflammatory diet as treatment for inflammatory bowel disease: A case series report. Nutr J 2014; 13:5.
74. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014; 40:843-854.
75. Polytarchou C, Koukos G, Iliopoulos D. Systems biology in inflammatory bowel diseases: ready for prime time. Current opinion in gastroenterology 2014; 30:339-346.
76. Rolland T, Tasan M, Charloteaux B, et al. A proteome-scale map of the human interactome network. Cell 2014; 159:1212-1226.
77. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: An integrated view of etiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2017. [in press]